Results 171 to 180 of about 145,366 (199)

Amikacin

Reactions Weekly, 2018
  +4 more sources

The role of amikacin in the treatment of nontuberculous mycobacterial disease

Expert Opinion on Pharmacotherapy, 2021
Jelmer Raaijmakers, Jodie A Schildkraut, Wouter Hoefsloot   +2 more
exaly  

Amikacin

Reactions Weekly, 1993
openaire   +1 more source

Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro

Pharmacological Research, 1995
Elżbieta A Trafny, Jacek Grzybowski
exaly  

Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China

Journal of Global Antimicrobial Resistance, 2020
Yaoju Tan, Chiranjibi Chhotaray, Xingshan Cai   +2 more
exaly  

High-level amikacin resistance in Pseudomonas aeruginosa associated with a 3′-phosphotransferase with high affinity for amikacin

International Journal of Antimicrobial Agents, 2000
Carmen Torres, Fernando Baquero, Deborah L Lerner   +2 more
exaly  

Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients

Journal of Global Antimicrobial Resistance, 2018
J Ruiz, Paula Ramirez, Mónica Gordon
exaly  

IR, Raman and SERS analysis of amikacin combined with DFT-based calculations

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019
Lucian-Cristian Pop, Mónica Baia
exaly  

Amikacin

Reactions Weekly, 2007
openaire   +1 more source

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin

Antimicrobial Agents and Chemotherapy, 2018
Tridia Van Der Laan, Onno W Akkerman, Mathieu S Bolhuis   +2 more
exaly